UNSPSC 51111731: Bevacizumab

This classification denotes a monoclonal antibody anti-vegf with the molecular formula C6638H10160N1720O2108S44, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2S9ZZM9Q9V, more generally known as bevacizumab. European Medicines Agency schedules bevacizumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB16402MIG. The term BEVACIZUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 15 no. 1, 2001, list 45.

Most nations schedule Bevacizumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, BEVACIZUMAB remains the US FDA Preferred Term for this commodity.. Bevacizumab bears US NLM identifiers UMLS ID C0796392 and NCI Concept Code C2039.

UNSPSC 51111731 Bevacizumab is a Commodity code that in recent state and local procurement activity does not align with its nominal pharmaceutical scope. The code's name identifies a specific monoclonal antibody cancer therapeutic, yet the recent opportunities tagged to this code solicit naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas Health and Human Services Commission), general medical and first aid supplies for fire rescue operations (City of Tampa), and generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing (Minnesota Multistate Cooperative Purchasing Alliance). The mismatch between the code's specificity—a single branded or generic drug product—and the breadth of pharmaceutical and medical procurement actually occurring under it suggests either inconsistent code application in state and local systems or a systemic indexing problem that obscures the actual scope of work being solicited.

Geographic activity spans Florida, Texas, Minnesota, and Oregon through the MMCAP cooperative. Issuing bodies include county health departments (Seminole County), state health and human services agencies (Texas HHS Commission), municipal fire and rescue divisions (City of Tampa), and state procurement offices administering multistate cooperatives (Minnesota Department of Administration). The most recent opportunities include Seminole County's July 2026 IFB for 1,900 units of naloxone and 800 drug deactivation systems annually with a July 26 response date; Texas HHS's April 2026 RFI on direct-to-manufacturer prescription programs with an April 3 response deadline; City of Tampa's March 2026 ITB for 169 line items of medical and first aid supplies with an estimated contract value of $700,000, designated as a sheltered market for certified Small Local Business Enterprises; and MMCAP's January 2026 RFP for generic multi-source pharmaceuticals and OTC products with a March 26 response deadline, requiring compliance with cGMP, DSCSA, and FDA requirements plus $5,000,000 commercial general liability coverage. The code's actual recent activity does not reflect bevacizumab procurement specifically and warrants verification before resource allocation.